Abstracts Archive - Page 1051 of 2425 - ACR Meeting Abstracts

Abstract Number: 696 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis
Chenyang Lu^1,2, Beth Wallace^3,4,5, Wenyi Fu^2,6 and Yi Liu¹, ¹Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, ²Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ³VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, ⁴Department of Internal Medicine, Division of Rheumatology, Michigan Medicine, Ann Arbor, MI, ⁵Institute for Healthcare Policy and Innovation, Michigan Medicine, Ann Arbor, MI, ⁶Department of Rheumatology and Immunology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China, Shenyang, China
Background/Purpose: Many targeted synthetic DMARD (tsDMARD) and biological DMARD (bDMARD) were recently approved for treatment of active psoriatic arthritis (PsA), but their comparative efficacy and…
Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Clara Pérez-Velásquez¹, Maria Luz Garcia Vivar², Silvia Perez Barrio³, Eva Galindez-Agirregoikoa¹, Esther Ruíz Lucea¹, Ignacio Torre-Salaberri⁴, Olaia Fernández-Berrizbeitia¹, Ana Rosa Inchaurbe Pellejero², Juan Blanco Madrigal¹, Edurne Guerrero Basterretxea², Itziar Calvo Zorrilla², Oihane Ibarguengoitia², David Montero², Natalia Rivera-García¹, Maria Jesus Allande Lopez Linares¹ and Iñigo Gorostiza-Hormaetxe⁵, ¹Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Dermatology, University Hospital of Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁵Unit of Research, University Hospital of Basurto, Bilbao, Spain
Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…
Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Michael D. George¹, Joshua Baker² and Alexis Ogdie³, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
Abstract Number: 699 • 2018 ACR/ARHP Annual Meeting
New Onset/Recurrence of Inflammatory Arthralgia/Spondyloarthritis in Patients Treated with Vedolizumab for Intestinal Bowel Disease
Silvia Tamanini¹, Micaela Fredi², Chiara Bazzani¹, Maria Grazia Lazzaroni³, Melissa Fernandes⁴, Cecilia Nalli³, Angela Tincani³ and Franco Franceschini², ¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Brescia, Italy, Rheumatology and Clinical Immunology, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁴Autoimmune Unit/Internal Medicine Department, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (C.H.L.C), Lisbona, Portugal
Background/Purpose: Vedolizumab (VDZ) is a monoclonal antibody approved for inflammatory bowel disease, with a gut-specific mechanism of action, binding to α4β7 integrine expressed on gut-homing…
Abstract Number: 700 • 2018 ACR/ARHP Annual Meeting
Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial
Guro Løvik Goll¹, Nils Bolstad², Ines Iria^3,4, Rolf Klaasen⁵, Kristin Kaasen Jørgensen⁶, Inge C Olsen⁷, Ana Valido⁸, Maria J Saavedra⁹, João E. Fonseca¹⁰, Merete Lorentzen¹¹, Cato Mork¹², Knut EA Lundin¹³, David J Warren¹⁴, Espen A. Haavardsholm¹⁵, Jorgen Jahnsen¹⁶, Tore Kvien¹⁵ and João Gonçalves¹⁷, ¹Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, ³Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, ⁴iMed- Research Institute for medicines, Lisbon, Portugal, ⁵Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ⁶Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ⁷Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, ¹⁰Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, ¹¹Dept of Dermatology, Rikshospitalet, Oslo, Norway, ¹²Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, ¹³Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, ¹⁴Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ¹⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, ¹⁷Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal
Background/Purpose: The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis…
Abstract Number: 701 • 2018 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Vibeke Strand¹, M. Elaine Husni², Jenny Griffith³, Yan Song⁴, Rakesh Singh⁵, Jing Zhao⁶ and Keith A. Betts⁷, ¹Stanford University, Palo Alto, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³AbbVie, Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Analysis Group Inc, Boston, MA, ⁷Analysis Group, Inc., Los Angeles, CA
Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…
Abstract Number: 702 • 2018 ACR/ARHP Annual Meeting
Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Dongze Wu¹, Priscilla Wong¹, James F Griffith², Jiang Yue¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²Department of Imaging and Interventional Radiology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, ³Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Psoriatic arthritis (PsA) often leads to structural damage with resultant disability and reduced quality of life. Biologic disease modifying anti-rheumatic drugs (bDMARDs), including tumor…
Abstract Number: 703 • 2018 ACR/ARHP Annual Meeting
Articular Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Anastasia Dupré¹, Michael Collins², Franck Carbonnel³, Xavier Mariette^4,5 and Raphaele Seror¹, ¹Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Rheumatology, Université Paris Sud, Le Kremlin Bicetre, France, ²Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-Enterology, Université Paris Sud, Le Kremlin Bicêtre, France, ³Hopitaux Universitaires Paris Sud, Kremlin Bicetre, France, Gastro-enterology, Université Paris Sud, Le Kremlin Bicêtre, France, ⁴Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, ⁵Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France
Background/Purpose: Vedolizumab is a humanised IgG1 monoclonal antibody anti-α4β7 integrin agent used in inflammatory bowel disease (IBD). It modulates gut inflammation by preventing leukocyte migration…
Abstract Number: 704 • 2018 ACR/ARHP Annual Meeting
Metabolomics Analysis of Insulin Resistance in Mild/Inactive Non-Diabetic Systemic Lupus Erythematosus Women
Claudia Mendoza Pinto¹, Mario García-Carrasco², Gerardo Díaz-Merino³, Pamela Soto-Santillan⁴, Rossy Mejia-Ocampo⁵, Pamela Munguía-Realpozo³ and Alejandro Ruiz-Arguelles⁵, ¹Systemic Autoimmune Diseases Research Unit,, UMAE, HE CMN Manuel Ávila Camacho-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, ³Systemic Autoimmune Diseases Research Unit,, Hospital de Especialidades UMAE CMN, Instituto Mexicano del Seguro Social, Puebla, Mexico, ⁴Systemic Autoimmune Diseases Research Unit, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁵Laboratorios Clínicos de Puebla, Puebla, Mexico
Background/Purpose: SLE patients present a higher prevalence of insulin resistance (IR) and metabolic syndrome (MetS) than age- and sex-matched healthy controls. Advances in technology are…
Abstract Number: 705 • 2018 ACR/ARHP Annual Meeting
Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Claudia Mendoza Pinto^1,2, Nicolás Molano-González³, Adriana Rojas-Villarraga⁴, Verónica Vallejo-Ruiz⁵, Socorro Méndez-Martínez⁶ and Mario García-Carrasco^1,7, ¹Systemic Autoimmune Diseases Research Unit,, UMAE, HE CMN Manuel Ávila Camacho-CIBIOR, Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Departament of Research, Facultad de Medicina, Benemerita Universidad Autonoma de Puebla, Puebla, Mexico, ³Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia, ⁴Instituto de Investigaciones de la Fundación Universitaria de Ciencias de la Salud (FUCS), Bogotá, Colombia, ⁵Virology Laboratory, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Metepec, Puebla, Mexico, ⁶Research in Health Coordination,, Delegation of Puebla, Instituto Mexicano del Seguro Social, Puebla, Mexico, ⁷Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Human papillomavirus (HPV), a common sexually-transmitted infection, is considered a necessary cause of cervical cancer. The objectives of this systematic review and meta-regression were:…
Abstract Number: 706 • 2018 ACR/ARHP Annual Meeting
Increased Incidence and Prevalance of Resistant Hypertension in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Jocelyn S. Gandelman¹, Omair A. Khan², Megan Shuey³, Jacquelyn E. Neal², Alyson Dickson⁴, April Barnado⁵, Li Wang², William Dupont², C. Michael Stein⁴ and Cecilia P. Chung⁴, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ³Department of Pharmacology, Vanderbilt University, Nashville, TN, ⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁵Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Resistant hypertension (RHTN) is associated with increased risk of cardiovascular events in the general population. Patients with systemic lupus erythematous (SLE) have increased cardiovascular…
Abstract Number: 707 • 2018 ACR/ARHP Annual Meeting
Subclinical Parameters of Arterial Stiffness and Arteriosclerosis Correlate with QRISK3 in Systemic Lupus Erythematosus
Monica Vazquez-Del Mercado^1,2, Felipe Perez-Vazquez³, Eduardo Gomez-Bañuelos¹, Efrain Chavarria-Avila³, Arcelia Llamas-Garcia⁴, Karla I. Arrona-Rios⁴, Gustavo I Diaz-Rubio³, Sergio Duran-Barragan⁴, Rosa E Navarro-Hernandez³, Bethel Jordan-Estrada³, Natalia Prado-Bachega⁵, Miguel A. A. Gonzalez-Beltran³, Carlos G Ramos-Becerra⁶, Fernando Grover-Paez⁶, David Cardona-Muller⁷ and Ernesto German Cardona-Muñoz⁷, ¹Servicio de Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ²Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Mexico, ³Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁴Servicio en Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁵Anesthesiology, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁶Centro Universitario de Ciencias de la Salud, INTEC, Universidad de Guadalajara, Guadalajara, Mexico, ⁷Departamento de Fisiología, Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Jalisco, Mexico
Background/Purpose: It is well known that cardiovascular diseases (CVD) are a major contributor of death in systemic lupus erythematosus (SLE) as well in other rheumatic…
Abstract Number: 708 • 2018 ACR/ARHP Annual Meeting
The Montreal Cognitive Assessment Test. a Useful Tool in Screening of Cognitive Impairment in Patients with Systemic Lupus Erythematosusshort Title: Cognitive Impairment in SLE
Nicolas Paez-Venegas¹, Bethel Jordan-Estrada², Efrain Chavarria-Avila², Felipe Perez-Vazquez², Eduardo Gomez-Bañuelos³, Rafael Medina-Davalos¹, Jose A. Ontiveros-Gonzalez⁴, Gustavo I Diaz-Rubio², Rosa E Navarro-Hernandez² and Monica Vazquez-Del Mercado³, ¹Instituto Jalisciense de Salud Mental, ZAPOPAN, Mexico, ²Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ³Servicio de Reumatología, 004086 PNPC CONACyT, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico, ⁴Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, chronic and multisystemic disease, which can be related with a long range of neuropsychiatric manifestations, including cognitive…
Abstract Number: 709 • 2018 ACR/ARHP Annual Meeting
Differential Characteristics of Lupus Psychosis and Steroid Psychosis
Shunsei Hirohata^1,2,3, Yoshinori Kanai⁴, Akiko Mitsuo⁵, Yoshiaki Tokano⁴ and Hiroshi Hashimoto⁴, ¹Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Nobuhira Hospital, Tatsuno, Japan, ³Kitasato University School of Medicine, Sagamihara, Japan, ⁴Juntendo University School of Medicine, Tokyo, Japan, ⁵Rheumatology, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Background/Purpose: Psychiatric manifestations are relatively common in patients with systemic lupus erythematosus (SLE). Since there are a number of factors causing psychiatric manifestations other than…
Abstract Number: 710 • 2018 ACR/ARHP Annual Meeting
An Analysis of Cell-of-Origin in Diffuse Large B-Cell Lymphoma in Systemic Lupus Erythematosus, Including Molecular and Clinical Factors Associated with Survival
Basile Tessier-Cloutier¹, David Twa², Eva Baecklund³, Randy Gascoyne⁴, Nathalie A. Johnson⁵, Carin Backlin³, Diane L. Kamen⁶, Ann E. Clarke⁷, Rosalind Ramsey-Goldman⁸, Jennifer LF Lee⁹, Pedro Farinha⁴ and Sasha Bernatsky¹⁰, ¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ²Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada, ⁵Department of Oncology, McGill University, Montreal, QC, Canada, ⁶Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸FSM, Northwestern University, Chicago, IL, ⁹Medicine, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of diffuse large B-cell lymphoma (DLBCL). DLBCL is routinely classified by cell-of-origin (COO), with non-germinal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].